Invest Like a Rockefeller With These 'No Contest' Companies

In today's Masters Series, adapted from the September 10, 2020 issue of the free DailyWealth e-letter, Dave shares a few basic indicators he uses to identify winning stocks... reveals how you can apply those clues to your investment strategy... and explains why you must have a deep understanding of patents to succeed in biotech investing... [Stansberry Research Logo] Delivering World-Class Financial Research Since 1999 [Stansberry Master Series] Editor's note: [Our resident biotech expert Dave Lashmet sticks to the fundamentals](... Dave's route to Stansberry Research was unique. He's a scientist and a former professor who has been tracking medical breakthroughs for more than 20 years – on the lookout for new, safe medicines that can make early investors a fortune. His track record speaks for itself. Roughly 1 in every 3 of his recommendations goes on to double or better in value. And his investing strategy has produced two of the five biggest winners in our firm's history... In today's Masters Series, adapted from the September 10, 2020 issue of the free DailyWealth e-letter, Dave shares a few basic indicators he uses to identify winning stocks... reveals how you can apply those clues to your investment strategy... and explains why you must have a deep understanding of patents to succeed in biotech investing... --------------------------------------------------------------- Invest Like a Rockefeller With These 'No Contest' Companies By Dave Lashmet, editor, Stansberry Venture Technology When most people hear "venture capital," they think of Silicon Valley... They think of men in $5,000 suits trying to predict the next Apple or Facebook. But the concept of venture-capital investing goes back more than 75 years to one of America's blue-blood families. Laurance Rockefeller, grandson of Standard Oil founder John D. Rockefeller Sr., developed the strategy to grow his family's wealth. Rockefeller began his career in finance at age 26, when he inherited his grandfather's seat on the New York Stock Exchange. During World War II, he became fascinated with incredible developments in science, technology, and medicine. It shouldn't surprise you that the stocks I recommend in my biotech newsletter come from a few key sectors... And they look a lot like the emerging technologies that Rockefeller focused on. We use a few basic clues to identify the winning stocks in these areas. As you'll see, these traits amount to something important – a clear path to beating the competition. Let me explain... --------------------------------------------------------------- Recommended Links: # [This Breakthrough Could Be BIGGER Than AI]( Renowned futurist and NYU professor Scott Galloway went on record saying this would be BIGGER than AI. And as usual, millions of investors are giving up at the exact wrong time. It's easily the biggest story in the world you're likely NOT paying attention to unless you're personally affected. And it could lead to a series of 200%... 500%... even 1,000% gains. But don't take our word – hear it from a Stansberry Research employee who's part of this story... and who says this breakthrough tech saved his life and let him see his sons grow up. [Breakthrough story here](. --------------------------------------------------------------- # [Dollar Reboot Underway]( Forget the digital dollar... the end of cash... or the BRICS plot to replace the dollar altogether. There's another, much more important story unfolding in the U.S. financial system today... one that involves a scheme backed by the Federal Reserve, U.S. Treasury, and 41 major banks. And it could have seismic implications not just for the U.S. dollar, but for your savings, retirement, and whole way of life. [Here's the full story](. --------------------------------------------------------------- First of all, we focus on three main types of companies: small drug companies, medical-device makers, and new high-tech devices. We love developing-drug stocks for several reasons. First, safe drugs save lives, so demand is inelastic. This means revenues go up even as prices rise. Second, over the next 20 to 30 years, the older segment of our population is going to grow dramatically. The Baby Boomer generation will continue to spend a fortune on everything from pharmaceuticals to lifesaving devices. Third, new drugs are protected monopolies. Patent-holders are guaranteed exclusive rights to sell a new drug for years before a generic version can hit the market and undercut profits. That's important – because all the competition has to undergo testing before it can be released. So there are no surprises about new players coming in the field. You can't build a new drug in your garage – not if you want U.S. Food and Drug Administration ("FDA") approval to sell it legally... Medical devices are a similar story. Patents give economic monopolies to the companies that sell these products. And they make the competitive landscape relatively easy to read. In medical sectors, we look for patented lifesaving drugs. We also look for devices with strong positive effects in human trials – and with low side-effect burdens to protect against future competition. When you get outside of the medical realm... new technologies do not usually address lifesaving needs. But there can still be a regulatory requirement that guarantees a technology will be put into use. Imagine who the winners will be if the U.S. National Highway Traffic Safety Administration mandates lane-departure warning technology, just like it did with seat belts or air bags. That's why we look for companies with breakthrough technologies that can be adopted readily by the market. In other words, consumers need them, and they're willing to pay a lot of money for them. When investing in all these types of companies, a deep understanding of the companies' patents will be key. These patents (and related forms of protection of intellectual property) are how we know a company's innovations are protected... that the folks designing these breakthroughs will be the ones to bring them to market. That way, we can be more comfortable investing alongside them. Patents are the bread and butter of successful biotech investing. Operating businesses are afraid to discuss them, so Wall Street doesn't seem to understand their value. The trick is, a patent is grounded in science, medicine, or engineering. It's not a financial instrument. And it's only valuable if it addresses a need – like an antibiotic that fights infections. One way or another, we want to secure our stake in the asset that a future market will desire. So we're doing more than just buying stocks in Stansberry Venture Technology. We also want to understand the patents and their timelines. One sector you won't see us ranging into as often is software. Think about a smartphone application that can order you up a private-car service, like Uber or Lyft. Nothing holds back competition... so there's no guarantee who will win. Will Lyft beat Uber, or will Uber beat Lyft in the ride-hailing space? Trying to guess is a fool's errand. For that matter, a third company might come along and wipe out both. That's not true of safe new drugs, devices, or core revolutions in hardware technology... Although such technologies are much more expensive to develop, they are not fads. And their intellectual property is much harder to steal. This is why some venture capitalists are now holding on to early-stage drugs, too... At least, they are trying to. But human clinical trials are so expensive, these small drug companies almost have to go public to share the risk. We are happy with risk, as long as the reward is greater and we have a reasonable chance to make far more money than we put at risk. That's the core of what we do in my Venture Technology newsletter... We share a common understanding with early-stage venture capitalists. We give up some of the reward, but we also retire most of the risk... Plus, we stay more liquid. This is how we find "no contest" companies in emerging technologies – the kind that can soar to spectacular gains. And it's how you can learn to invest like a Rockefeller. Good investing, David Lashmet --------------------------------------------------------------- Editor's note: Dave has recommended the biggest closed winner in Stansberry Research's history. And he has recommended 31 stocks that doubled or more. Now, his research is pointing toward the most lucrative medical breakthrough of the coming decade... It's a new cure for a dangerous condition that impacts millions of Americans. And one of our own employees recently went on camera to share how this new development saved his life. [Learn more here](... You have received this e-mail as part of your subscription to Stansberry Digest. If you no longer want to receive e-mails from Stansberry Digest [click here](. Published by Stansberry Research. You’re receiving this e-mail at {EMAIL}. Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com. This address is for feedback only. For questions about your account or to speak with customer service, call 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or e-mail info@stansberryresearch.com. Please note: The law prohibits us from giving personalized financial advice. © 2024 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201 or [stansberryresearch.com](. Any brokers mentioned constitute a partial list of available brokers and is for your information only. Stansberry Research does not recommend or endorse any brokers, dealers, or investment advisors. Stansberry Research forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Stansberry Research (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.